Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 July 2025

The European Medicines Agency's CHMP recommended 13 new medicines for approval in July 2025, including significant advancements for rare diseases such as the first oral treatment for hereditary angioedema and a twice-yearly HIV-1 pre-exposure prophylaxis, alongside a positive opinion for postpartum depression treatment. Concurrently, Kisunla (donanemab) received a re-examination approval for early Alzheimer's, while three notable candidates, including Elevidys for Duchenne muscular dystrophy, received negative opinions, underscoring the high-stakes and mixed outcomes in pharmaceutical development. The meeting also addressed COVID-19 vaccine updates and approved the first inhaled medicine with an environmentally friendly propellant, indicating broader regulatory and industry shifts.

Analysis

The European Medicines Agency's (EMA) CHMP meeting in July 2025 yielded a net positive outcome for the pharmaceutical sector, with 13 new medicines recommended for approval against three negative opinions. Key positive catalysts include the recommendation for Eli Lilly's (LLY) Kisunla (donanemab) for early Alzheimer's disease after a re-examination, a significant milestone targeting a major unmet medical need, albeit restricted to a specific genetic profile. KalVista Pharmaceuticals (KALV) stands out with a positive opinion for Ekterly, the first oral treatment for hereditary angioedema in the EU, representing a substantial improvement in patient convenience over existing injectable therapies. Similarly, Gilead Sciences (GILD) received a strong endorsement for Yeytuo (lenacapavir), a twice-yearly injectable for HIV-1 pre-exposure prophylaxis, which could significantly enhance patient compliance and market uptake. Conversely, the committee issued notable rejections, including a negative opinion for Roche's (RHHBY) Elevidys for Duchenne muscular dystrophy, a material setback for a high-profile rare disease candidate. Furthermore, a new review of SIGA Technologies' (SIGA) mpox treatment, Tecovirimat, was initiated due to emerging data suggesting a lack of effectiveness, creating significant uncertainty for the product's future. The meeting also highlighted broader industry trends, with positive opinions for four biosimilars, signaling intensifying competition for originator drugs, and the approval of updated mRNA COVID-19 vaccines from companies like Moderna (MRNA).

Key Decisions for Investors

• The positive CHMP opinions for KalVista's (KALV) first-in-class oral Ekterly, Gilead's (GILD) long-acting Yeytuo, and Eli Lilly's (LLY) Alzheimer's drug Kisunla serve as significant de-risking events, potentially unlocking substantial European market access and justifying a bullish outlook on these specific assets.
• Investors should consider the negative opinion for Roche's (RHHBY) Elevidys a material headwind for its rare disease pipeline, while the newly initiated review of SIGA Technologies' (SIGA) Tecovirimat introduces considerable downside risk to the product's European revenue projections.
• The approval of four biosimilars underscores the growing competitive pressure on originator biologics, presenting a strategic headwind for incumbents but a clear opportunity for the developers who received positive opinions.
• While the 13 positive recommendations are favorable, final marketing authorization from the European Commission is still required; therefore, positions should be managed with an awareness of this final regulatory step, particularly for smaller-cap companies where a single product approval is pivotal.